OncoMatch

OncoMatch/Clinical Trials/NCT06104241

BGT007 Cells for the Treatment of Refractory Digestive System Tumors

Is NCT06104241 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies BGT007 for gastrointestinal cancer.

Early Phase 1RecruitingThe Affiliated Hospital of Xuzhou Medical UniversityNCT06104241Data as of May 2026

Treatment: BGT007 — This is an exploratory clinical study evaluating the safety and initial efficacy of BGT007 injection in the treatment of recurrent/metastatic/refractory digestive system tumors

Check if I qualify

Extracted eligibility criteria

Cancer type

Colorectal Cancer

Gastric Cancer

Hepatocellular Carcinoma

Pancreatic Cancer

Cholangiocarcinoma

Esophageal Carcinoma

Disease stage

Metastatic disease required

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

Min 2 prior lines

Must have received: standard treatment — second-line or above

previously received second-line or above standard treatment failure or intolerance

Cannot have received: chimeric antigen receptor modified T cells (CAR-T, TCR-T)

Received chimeric antigen receptor modified T cells (including CAR-T, TCR-T) within six months

Lab requirements

Blood counts

Neutrophil count ≥1.0×10^9/L; Platelet count ≥80×10^9/L; Hemoglobin ≥90g/L

Kidney function

Creatinine clearance (CCR) ≥50 mL/min

Liver function

AST/ALT ≤2.5× ULN (no liver mets), ≤5× ULN (with liver mets); TBIL ≤1.5× ULN (no liver mets), ≤2× ULN (with liver mets or Gilbert syndrome)

Blood routine examination Neutrophil count (NEU #) ≥1.0×10^9/L Platelet count (PLT) ≥80×10^9/L Hemoglobin concentration ≥90g/L Liver function: subjects without liver metastases Aspartate aminotransferase (AST) ≤2.5× Upper Limit of Normal (ULN) Alanine aminotransferase (ALT) ≤2.5× Upper Limit of Normal (ULN) Total bilirubin (TBIL) ≤1.5×ULN Liver function: Subjects with liver metastases Aspartate aminotransferase (AST) ≤5× Upper limit of normal (ULN) Alanine aminotransferase (ALT) ≤5× Upper limit of normal (ULN) Liver function: Subjects with liver metastases or Gilbert syndrome Total bilirubin (TBIL) ≤2×ULN renal function Creatinine clearance (CCR) ≥50 mL/min

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify